Carcinoma, Renal Cell: all 1,992 studies
Page 10 of 20. Open to participants first (387), then studies with results posted, then the rest; newest registration first within each.
- Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO)TerminatedNCT06114940Phase 2
- Exploring the Influence of Clinical Factors on the Prognosis of Papillary Renal Cell CarcinomaCompletedNCT06111560
- Study of DF6215 in Patients With Advanced Solid TumorsCompletedNCT06108479Phase 1
- 89Zr-DFO-girentuximab Expanded Access Program (EAP)No longer availableNCT06090331
- Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A LossWithdrawnNCT06090318Phase 1/2
- Virtual Interactive 3D Modelling to Improve Outcomes in Robotic-Assisted Partial NephrectomyCompletedNCT06056505Not applicable
- Moesin Expression in Clear Cell Renal Cell CarcinomaCompletedNCT06055660
- Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced MalignanciesTerminatedNCT06052852Phase 1
- Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell CarcinomaSuspendedNCT06049576Phase 1
- Cadonilimab (AK104) Plus Lenvatinib in Previously Immunotherapy-Treated Advanced/Metastatic Clear Cell Renal Cell CarcinomaActive, not recruitingNCT06035224Phase 2
- Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer TypesTerminatedNCT06034860Phase 1
- Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to BenchsideCompletedNCT06020651Not applicable
- The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint InhibitorsSuspendedNCT05967533Phase 1
- A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7SuspendedNCT05958199Phase 1
- An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF)No longer availableNCT05941637
- Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)TerminatedNCT05935748Phase 2
- Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid TumorsTerminatedNCT05909995Phase 1
- A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension StudyActive, not recruitingNCT05899049Phase 3
- Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced CancersActive, not recruitingNCT05891171Phase 1
- Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial NephrectomyActive, not recruitingNCT05887245
- Renal Cell Carcinoma Metastases to PancreasCompletedNCT05882747
- A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor NaiveTerminatedNCT05879822Phase 2
- 68Ga-NY104 PET/CT in Patients With Metastasis/Recurrence Clear Cell Renal Cell Carcinoma SuspicionStatus unknownNCT05879497Phase 2
- A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid TumorsActive, not recruitingNCT05867303Phase 1
- Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR StudyActive, not recruitingNCT05863351Phase 3
- Analyzing Clinical Outcomes and Genomic Data of American Indian Patient PopulationActive, not recruitingNCT05863052
- Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell CarcinomaCompletedNCT05861778Phase 1
- A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).CompletedNCT05858749
- Safety, PK and Efficacy of AI-061 in Advanced Solid TumorsCompletedNCT05858736Phase 1
- A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed SurgicallyTerminatedNCT05826600Phase 1/2
- Stereotactic Body Radiotherapy (SBRT) for Medically Inoperable Localised Renal Tumors (SABINA Trial)Active, not recruitingNCT05817604
- Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell CarcinomaStatus unknownNCT05816642Not applicable
- A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell CarcinomaActive, not recruitingNCT05808608Phase 1/2
- A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell CarcinomaActive, not recruitingNCT05805501Phase 2
- A Bioequivalence Study of Sunitinib Malate Capsules.CompletedNCT05800106Phase 1
- A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid TumorsCompletedNCT05795595Phase 1/2
- A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid TumorsActive, not recruitingNCT05789069Phase 1
- Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor MalignanciesActive, not recruitingNCT05783622Phase 1
- Multiomics Approach in Metastatic Clear Renal Cell CarcnomaActive, not recruitingNCT05782400
- Study of RO7515629 in Participants With HLA-G Positive Solid TumorsTerminatedNCT05769959Phase 1
- CD8 Minibody Repeatability StudyTerminatedNCT05744128Phase 2
- Valveless Trocar Versus Standard Trocar in Robot-assisted Complex Partial NephrectomyStatus unknownNCT05732857Not applicable
- Three-dimensional Virtual Imaging to Improve the Accuracy of Standard CT-based Nephrometric Scores: a Prospective Multicentric Observational StudyCompletedNCT05729763
- A Small-molecule Carbonic Anhydrase IX Targeting PET Tracer in Clear Cell Renal Cell CarcinomaCompletedNCT05728515Early Phase 1
- Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)TerminatedNCT05721222Phase 1/2
- Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving ImmunotherapyActive, not recruitingNCT05703269Not applicable
- Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCCSuspendedNCT05663710Phase 1/2
- A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.Active, not recruitingNCT05661955Phase 1/2
- A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid TumorsActive, not recruitingNCT05653882Phase 1
- IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC PatientsTerminatedNCT05641545Phase 1
- 68Ga-labeled NY104 PET Imaging in PatientsStatus unknownNCT05638256Early Phase 1
- Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic CancerActive, not recruitingNCT05620134Phase 1/2
- A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid TumorsActive, not recruitingNCT05614102Phase 1
- Study of DF9001 in Patients With Advanced Solid TumorsCompletedNCT05597839Phase 1/2
- PRO-VISION: Patient Reported Outcomes-Based Monitoring of VEGF-Inhibitor Side Effects in ONcologyActive, not recruitingNCT05592665Not applicable
- Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid TumorsCompletedNCT05585034Phase 1
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT05581004Phase 1
- Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination ImmunotherapyCompletedNCT05579847
- A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced CancersActive, not recruitingNCT05544929Phase 1
- The Association of Marital Status With Kidney Cancer Surgery MorbidityCompletedNCT05526599
- Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)Active, not recruitingNCT05520099
- Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.Active, not recruitingNCT05501054Phase 1/2
- Oncological and Functional Outcomes of Laparoscopic Partial Nephrectomy in Renal Cell Carcinoma Stages T1 Versus T2a: Prospective Comparative Study.Status unknownNCT05486871Not applicable
- Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCCCompletedNCT05485896Phase 2
- Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid TumorsCompletedNCT05479812Phase 1
- A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)Active, not recruitingNCT05468697Phase 1/2
- A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid TumorsTerminatedNCT05462873Phase 1
- Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)CompletedNCT05461430
- Percutaneous Cryoablation of Central Kidney Tumours With Temporary Renal Artery OcclusionCompletedNCT05461027
- A Study to Collect Pre-existing Data on the Administration of Cabozantinib in Participants With Advanced Renal Cell Carcinoma (aRCC) Who Initiated Cabozantinib in 2nd Line in a Real-life Clinical Setting in France.CompletedNCT05444933
- A Clinical Study of 6MW3211 in Patients With Renal CancerStatus unknownNCT05440045Phase 2
- 68Ga-P16-093 and 18F-FDG PET/CT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma PatientsCompletedNCT05432947Not applicable
- A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in ArizonaWithdrawnNCT05418387Not applicable
- Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 TrialActive, not recruitingNCT05411081Phase 2
- "Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"CompletedNCT05410509Not applicable
- ITIL-306 in Advanced Solid TumorsTerminatedNCT05397093Phase 1
- An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UKCompletedNCT05394493
- A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid TumorsActive, not recruitingNCT05393427Phase 1
- Comparing Two Different Approaches in Robotic-Assisted Renal SurgeryCompletedNCT05377632Not applicable
- A Study of Lenvatinib in Combination With Pembrolizumab in Korean PatientsCompletedNCT05375136
- Collecting Ducts Carcinoma: in Depth Exploration and Biologically Driven Therapy (CICERONE)Status unknownNCT05372302
- Seleno-L Methionine (SLM)-Axitinib-PembrolizumabActive, not recruitingNCT05363631Phase 1/2
- A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128Active, not recruitingNCT05354102Phase 1
- Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid TumorsActive, not recruitingNCT05311618Phase 1
- A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid TumorsCompletedNCT05293496Phase 1
- Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical RespondersActive, not recruitingNCT05286294Phase 2
- First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsActive, not recruitingNCT05277051Phase 1
- Optimizing Pembrolizumab Therapy With Timing and Intensification With AxitinibWithdrawnNCT05263609Phase 2
- The Pharmacological Effects of Using Cabozantinib With a Light BreakfastCompletedNCT05263245Phase 2
- A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC)Status unknownNCT05262413Phase 1/2
- A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell CarcinomaCompletedNCT05256472Phase 2
- Biomarkers of Response to Systemic Treatments in FH-deficient RCCStatus unknownNCT05243173
- A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)Active, not recruitingNCT05239728Phase 3
- Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney CancerActive, not recruitingNCT05239533Phase 2
- P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid TumorsActive, not recruitingNCT05239143Phase 1
- A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid TumorsActive, not recruitingNCT05238883Phase 1
- A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.CompletedNCT05230186
- A Study of HFB301001 in Adult Patients With Advanced Solid TumorsTerminatedNCT05229601Phase 1
- Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase InhibitorsActive, not recruitingNCT05219318Phase 3
- CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer ImmunotherapyActive, not recruitingNCT05215470Phase 2